UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                    For quarterly period ended June 30, 2010

                                       or

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

          For the transition period from _____________ to _____________

                        Commission File Number 000-53486


                              ENOX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

           Nevada                                                26-0477124
(State or other jurisdiction of                               (I.R.S. employer
 incorporation or organization)                              identification no.)

                       303-1687 W. Broadway, Vancouver BC
                                 V6J 1X2 Canada
               (Address of principal executive offices)(Zip code)

                              Tel: + (604) 637-9744
                             Fax: +1 (888) 224-7259
              (Registrant's telephone number, including area code)

                                 Not Applicable
              (Former name, former address, and former fiscal year,
                         if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by checkmark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer or a smaller reporting company. See
definition of "large accelerated filer," "accelerated filer," and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                        Accelerated filer [ ]
Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

The issuer has  13,197,920  shares of common stock  outstanding as of August 16,
2010.
<PAGE>
                              ENOX BIOPHARMA, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                          INDEX TO FINANCIAL STATEMENTS
                                  JUNE 30, 2010

                                                                            Page
                                                                            ----

Balance Sheets as of June 30, 2010 (Unaudited) and December 31, 2009         3

Statements of Operations for the Three and Six Months Ended
June 30, 2010 and 2009, and from June 28, 2007 (inception) to
June 30, 2010 (Unaudited)                                                    4

Statements of Cash Flows for the Six Months Ended June 30, 2010 and 2009,
and from June 28, 2007 (inception) to June 30, 2010 (Unaudited)              5

Notes to the Financial Statements (Unaudited)                                6


                                       2
<PAGE>
                          PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

                              Enox Biopharma, Inc.
                          (A Development Stage Company)
                                 Balance Sheets

<TABLE>
<CAPTION>
                                                                         June 30, 2010        December 31, 2009
                                                                         -------------        -----------------
                                                                          (Unaudited)
<S>                                                                       <C>                   <C>
                                     ASSETS

CURRENT ASSETS:
  Cash                                                                    $   148,878           $   234,076
  Prepaid expenses                                                              9,333                16,333
                                                                          -----------           -----------
TOTAL CURRENT ASSETS                                                          158,211               250,409

EQUIPMENT - NET                                                                17,150                 1,144
                                                                          -----------           -----------

TOTAL ASSETS                                                              $   175,361           $   251,553
                                                                          ===========           ===========

                      LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES:
  Accounts payable                                                        $       149           $     1,400
  Accrued liabilities                                                          80,930                    --
  Loan payable - related party                                                100,000                    --
  Derivative liability - warrants                                              14,894                    --
                                                                          -----------           -----------
TOTAL CURRENT LIABILITIES                                                     195,973                 1,400
                                                                          -----------           -----------

STOCKHOLDERS' EQUITY:
  Preferred stock, ($0.0001 par value, 50,000,000 shares authorized,
   no shares outstanding)                                                          --                    --
  Common stock, ($0.0001 par value, 100,000,000 shares authorized,
   12,829,587 and 12,829,587 issued and outstanding)                            1,285                 1,283
  Additional paid in capital                                                1,190,215               844,898
  Deficit accumulated during the development stage                         (1,212,112)             (596,028)
                                                                          -----------           -----------
TOTAL STOCKHOLDERS' EQUITY                                                    (20,612)              250,153
                                                                          -----------           -----------

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                $   175,361           $   251,553
                                                                          ===========           ===========
</TABLE>


                 See accompanying notes to financial statements

                                       3
<PAGE>
                              Enox Biopharma, Inc.
                          (A Development Stage Company)
                            Statements of Operations
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                                June 28, 2007
                                                                                                               (Inception) to
                                                  Three months Ended June 30,     Six months Ended June 30,       June 30,
                                                    2010             2009           2010            2009            2010
                                                 -----------      -----------    -----------     -----------     -----------
<S>                                              <C>              <C>            <C>             <C>             <C>
OPERATING EXPENSES:
  General and administrative                     $   295,130      $    16,873    $   463,516     $    39,322     $   668,171
  Research and development                            98,396           41,462        137,673          60,629         529,047
                                                 -----------      -----------    -----------     -----------     -----------
TOTAL OPERATING EXPENSES                             393,526           58,335        601,189          99,951       1,197,218
                                                 -----------      -----------    -----------     -----------     -----------

LOSS FROM OPERATIONS                                (393,526)         (58,335)      (601,189)        (99,951)     (1,197,218)
                                                 ===========      ===========    ===========     ===========     ===========
OTHER INCOME (EXPENSE)
  Derivative expense                                 (15,141)              --        (15,141)             --         (15,141)
  Change on fair value of derivative liability           247               --            247              --             247
                                                 -----------      -----------    -----------     -----------     -----------
TOTAL OTHER INCOME (EXPENSE)                         (14,894)              --        (14,894)             --         (14,894)
                                                 -----------      -----------    -----------     -----------     -----------

Net Loss                                         $  (408,420)     $   (58,335)   $  (616,083)    $   (99,951)    $(1,212,112)
                                                 ===========      ===========    ===========     ===========     ===========

Net loss per common share - basic and diluted    $     (0.03)     $     (0.01)   $     (0.05)    $     (0.01)    $     (0.11)
                                                 ===========      ===========    ===========     ===========     ===========

WEIGHTED AVERAGE NUMBER OF COMMON SHARES
 OUTSTANDING DURING THE PERIOD - BASIC
 AND DILUTED                                      12,832,060       11,199,417     12,830,830      11,199,417      10,681,695
                                                 ===========      ===========    ===========     ===========     ===========
</TABLE>


                 See accompanying notes to financial statements

                                       4
<PAGE>
                              Enox Biopharma, Inc.
                            Statements of Cash Flows
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                                   June 28, 2007
                                                                                                   (Inception) to
                                                                Six Months Ended June 30,             June 30,
                                                              2010                   2009               2010
                                                          ------------           ------------       ------------
<S>                                                       <C>                    <C>                <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net loss                                                $   (616,083)          $    (99,951)      $ (1,212,112)
  Adjustments to reconcile net loss to net
   cash used in operating activities:
     Depreciation                                                  284                    544              2,980
     Share based payments                                      295,319                     --            346,884
     Derivative expense                                         15,141                     --             15,141
     Change in fair value of derivative liabilities               (247)                    --               (247)
  Changes in operating assets and liabilities:
     Accounts payable                                           (1,250)                    --                150
     Accrued liabilities                                        80,929                 (2,358)            80,929
     Prepaid expenses                                            7,000                 10,110             (9,333)
                                                          ------------           ------------       ------------
          NET CASH USED IN OPERATING ACTIVITIES               (218,907)               (91,655)          (775,608)
                                                          ------------           ------------       ------------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Purchase of equipment                                        (16,290)                    --            (20,127)
                                                          ------------           ------------       ------------
          NET CASH USED IN INVESTING ACTIVITIES                (16,290)                    --            (20,127)
                                                          ------------           ------------       ------------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Proceeds from loan payable - related party                   100,000                     --            100,000
  Proceeds from issuance of common stock and warrants           50,000                     --            665,883
  Proceeds from exercise of warrants                                --                     --            178,732
                                                          ------------           ------------       ------------
          NET CASH PROVIDED BY FINANCING ACTIVITIES            150,000                     --            944,615
                                                          ------------           ------------       ------------

NET INCREASE (DECREASE) IN CASH                                (85,197)               (91,655)           148,878

CASH - BEGINNING OF PERIOD                                     234,076                103,730                 --
                                                          ------------           ------------       ------------

CASH - END OF PERIOD                                      $    148,878           $     12,075       $    148,878
                                                          ============           ============       ============

SUPPLEMENTARY CASH FLOW INFORMATION:

Cash paid during the period for:
  Income taxes                                            $         --           $         --       $         --
                                                          ============           ============       ============
  Interest                                                $         --           $         --       $         --
                                                          ============           ============       ============
</TABLE>


                 See accompanying notes to financial statements

                                       5
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


NOTE 1 NATURE OF OPERATIONS

Enox  Biopharma,  Inc. (the "Company" or "Enox") was organized and  incorporated
under the laws of the State of Nevada on June 28, 2007.  The Company is focusing
on the development and  commercialization  of advanced Nitric Oxide technologies
for a variety  of medical  uses.  Enox's  patented  platform  technology  can be
utilized  across a wide spectrum of  applications  ranging from the treatment of
upper respiratory tract infections,  prevention of hospital acquired infections,
innovative  solutions  to assist in the  prevention  of the  common  cold and to
protect  people  from a diverse  array of life  threatening  and drug  resistant
infections.  The Company has not yet received required approvals to commercially
sell any of its products that are in development.

NOTE 2 BASIS OF PRESENTATION

The accompanying  unaudited  condensed  interim  financial  statements have been
prepared in accordance  with  accounting  principles  generally  accepted in the
United  States of America  and the rules and  regulations  of the United  States
Securities and Exchange  Commission for interim  financial  information and with
the instructions to Form 10-Q and Article 10 of Regulation S-X.

The  financial  information  as of December 31, 2009 is derived from the audited
financial  statements  presented in the Company's Annual Report on Form 10-K for
the year ended  December 31, 2009.  The unaudited  condensed  interim  financial
statements  should be read in  conjunction  with the Company's  Annual Report on
Form 10-K,  which contains the audited  financial  statements and notes thereto,
together  with the  Management's  Discussion  and  Analysis,  for the year ended
December 31, 2009.

Certain  information  or footnote  disclosures  normally  included in  financial
statements prepared in accordance with accounting  principles generally accepted
in the United States of America have been condensed or omitted,  pursuant to the
rules and  regulations  of the  Securities  and Exchange  Commission for interim
financial  reporting.  Accordingly,  they do not include all the information and
footnotes  necessary for a  comprehensive  presentation  of financial  position,
results of operations,  or cash flows. It is management's opinion, however, that
all material adjustments  (consisting of normal recurring adjustments) have been
made  which are  necessary  for a fair  financial  statement  presentation.  The
interim  results  for the  period  ended  June  30,  2010  are  not  necessarily
indicative of results for the full fiscal year.

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

DEVELOPMENT STAGE

The Company's financial statements are presented as those of a development stage
enterprise.  Activities  during the development  stage primarily  include equity
based financing and further implementation of the business plan.

                                       6
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


USE OF ESTIMATES

The  preparation of  consolidated  financial  statements in conformity with U.S.
generally accepted  accounting  principles requires management to make estimates
and assumptions that affect the amounts  reported in the consolidated  financial
statements and accompanying notes. Such estimates and assumptions impact,  among
others,  the  following:  the fair  value of  options  and  warrants  granted as
compensation, estimates of the probability and potential magnitude of contingent
liabilities  and  the  valuation  allowance  for  deferred  tax  assets  due  to
continuing operating losses.

Making estimates requires management to exercise significant  judgment. It is at
least  reasonably  possible  that the  estimate  of the  effect of a  condition,
situation or set of  circumstances  that existed at the date of the consolidated
financial  statements,  which management  considered in formulating its estimate
could  change  in the near  term due to one or more  future  confirming  events.
Accordingly, the actual results could differ significantly from our estimates.

RISKS AND UNCERTAINTIES

The  Company's  operations  are subject to  significant  risk and  uncertainties
including financial, operational,  technological, and regulatory risks including
the potential risk of business failure.  Also see Note 3 regarding going concern
matters.

RESEARCH AND DEVELOPMENT

Research and development is expensed as incurred.

SHARE-BASED PAYMENTS

Generally,  all forms of share-based  payments,  including  stock option grants,
restricted stock grants and stock appreciation rights are measured at their fair
value on the awards' grant date,  based on the  estimated  number of awards that
are  ultimately  expected to vest.  Share-based  compensation  awards  issued to
non-employees for services rendered are recorded at either the fair value of the
services  rendered or the fair value of the  share-based  payment,  whichever is
more readily  determinable.  The expense resulting from share-based payments are
recorded  in cost of goods sold or  general  and  administrative  expense in the
consolidated  statement of  operations,  depending on the nature of the services
provided.

DERIVATIVE FINANCIAL INSTRUMENTS

Fair value accounting requires  bifurcation of embedded  derivative  instruments
such as  conversion  features in  convertible  debt or equity  instruments,  and
measurement of their fair value for  accounting  purposes.  In  determining  the
appropriate fair value, the Company uses the Black-Scholes option-pricing model.
In assessing the  convertible  debt  instruments,  management  determines if the
convertible debt host instrument is conventional convertible debt and further if

                                       7
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


there  is  a  beneficial  conversion  feature  requiring  measurement.   If  the
instrument is not  considered  conventional  convertible  debt, the Company will
continue its evaluation  process of these  instruments  as derivative  financial
instruments.

Once determined,  the derivative  liabilities are adjusted to reflect fair value
at each  reporting  period end,  with any increase or decrease in the fair value
being  recorded  in  results of  operations  as an  adjustment  to fair value of
derivatives.  In addition, the fair value of freestanding derivative instruments
such as warrants, are also valued using the Black-Scholes  option-pricing model.
At June 30, 2010 and December 31, 2009, respectively, the Company had derivative
liabilities in the amounts of $14,894 and $0, respectively.

EARNINGS PER SHARE

In  accordance  with  accounting  guidance  now  codified as FASB ASC Topic 260,
"Earnings  per Share," basic  earnings  (loss) per share is computed by dividing
net  income  (loss) by  weighted  average  number  of  shares  of  common  stock
outstanding during each period. Diluted earnings (loss) per share is computed by
dividing net income  (loss) by the weighted  average  number of shares of common
stock, common stock equivalents and potentially dilutive securities  outstanding
during the period.

The Company had the following  potential  common stock  equivalents  at June 30,
2010 and December 31, 2009:

                                           June 30, 2010       December 31, 2009
                                           -------------       -----------------

     Warrants                                1,218,086             1,005,586
     Options                                   546,616                    --
                                            ----------            ----------

     Total common stock equivalents          1,764,702             1,005,586
                                            ==========            ==========

Since the Company reflected a net loss in for the period ended June 30, 2010 and
2009, respectively,  the effect of considering any common stock equivalents,  if
outstanding,  would have been anti-dilutive.  A separate  computation of diluted
earnings (loss) per share is not presented.

RECENT ACCOUNTING PRONOUNCEMENTS

In  January  2010,  the  Financial  Accounting  Standards  Board  (FASB)  issued
Accounting Standards Update No. 2010-06, "Improving Disclosures about Fair Value
Measurements   ("ASU  2010-06").   ASU  2010-06  amends  ASC  820,  "Fair  Value
Measurements"  ("ASC  820")  to  require  a  number  of  additional  disclosures
regarding fair value  measurements.  The amended guidance  requires  entities to
disclose the amounts of significant transfers between Level 1 and Level 2 of the
fair value  hierarchy and the reasons for these  transfers,  the reasons for any
transfers  in or out of  Level  3,  and  information  in the  reconciliation  of
recurring Level 3 measurements about purchases, sales, issuances and settlements
on a gross  basis.  The ASU also  clarifies  the  requirement  for  entities  to
disclose  information  about both the  valuation  techniques  and inputs used in

                                       8
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


estimating Level 2 and Level 3 fair value measurements. The amended guidance was
effective for financial  periods  beginning after December 15, 2009,  except the
requirement  to disclose Level 3  transactions  on a gross basis,  which becomes
effective for financial  periods  beginning after December 15, 2010. ASU 2010-06
did not  have a  significant  effect  on the  Company's  consolidated  financial
position or results of operations.

In April 2010,  FASB issued ASU No.  2010-17,  Revenue  Recognition -- Milestone
Method (Topic 605):  Milestone  Method of Revenue  Recognition.  ASU No. 2010-17
codifies  the  consensus  reached in Emerging  Issues Task Force Issue No. 08-9,
"Milestone Method of Revenue  Recognition." ASU No. 2010-17 provides guidance on
defining a milestone and  determining  when it may be  appropriate  to apply the
milestone   method  of  revenue   recognition   for   research  or   development
transactions.  Consideration that is contingent on achievement of a milestone in
its entirety may be  recognized  as revenue in the period in which the milestone
is  achieved  only if the  milestone  is judged to meet  certain  criteria to be
considered  substantive.  Milestones  should be considered  substantive in their
entirety and may not be bifurcated.  An arrangement may contain both substantive
and  non-substantive   milestones,   and  each  milestone  should  be  evaluated
individually to determine if it is substantive.  ASU No. 2010-17 is effective on
a prospective basis for milestones achieved in fiscal years, and interim periods
within those  years,  beginning  on or after June 15,  2010.  Early  adoption is
permitted.  The  Company  does not  expect  the  adoption  of this ASU to have a
material impact on its results of operations or financial condition.

NOTE 4 GOING CONCERN

As reflected in the  accompanying  financial  statements,  the Company has a net
loss of $616,083 and net cash used in  operations of $218,907 for the six months
ended June 30, 2010.  The Company also has a working  capital  deficit of 37,762
and a stockholders'  deficit of $20,612. The Company is in the development stage
and has not generated any revenues.

The  ability  of  the  Company  to  continue  its  operations  is  dependent  on
Management's  plans,  which  include the raising of capital  through debt and/or
equity markets with some  additional  funding from other  traditional  financing
sources, including term notes, until such time that funds provided by operations
are  sufficient to fund working  capital  requirements.  The Company may need to
incur  additional  liabilities  with  certain  related  parties to  sustain  the
Company's existence.
The Company will require additional funding to finance the growth of its current
and expected future  operations as well as to achieve its strategic  objectives.
The Company believes its current available cash along with anticipated  revenues
may be insufficient to meet its cash needs for the near future.  There can be no
assurance that financing will be available in amounts or terms acceptable to the
Company, if at all.

The  accompanying  financial  statements  have been  prepared on a going concern
basis,  which  contemplates  the  realization of assets and the  satisfaction of
liabilities in the normal course of business.  These financial statements do not
include any  adjustments  relating to the recovery of the recorded assets or the
classification  of the liabilities that might be necessary should the Company be
unable to continue as a going concern.

                                       9
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


NOTE 5 LOANS PAYABLE RELATED PARTY

In 2007, the Company's  Chief Executive  Officer  advanced $100. The advance was
non-interest bearing, unsecured and due on demand. The $100 was repaid in 2008.

In May 2010, the Company  executed a loan with its Chief  Executive  Officer for
$100,000. The loan bears interest at 12%, is unsecured and due May 15, 2011.

NOTE 6 DERIVATIVE LIABILITY

On June 23, 2010,  the Company issued 12,500 Series "A" warrants to an investor,
as more fully discussed in Note 7.

In connection  with ASC 815,  "Determining  Whether an  Instrument  (or Embedded
Feature) Is Indexed to an Entity's Own Stock," the Company  determined  that the
warrants  (ratchet  down of exercise  price based upon lower  exercise  price in
future offerings) are not indexed to the Company's own stock and, therefore,  is
an embedded  derivative  liability (the "Embedded  Derivative"),  which requires
bifurcation and to be separately accounted for.

The  Company  measured  the fair  value of the  derivative  liabilities  using a
Black-Scholes valuation model.

The fair value of the derivative liabilities are summarized as follow:

     Fair value at the commitment date for the warrants:       $ 15,141
     Mark to market adjustments at June 30, 2010:                  (247)
                                                               --------

     Derivative liability balance at June 30, 2010             $ 14,894
                                                               ========

The Company recorded a derivative expense at the commitment date of $15,141.

The fair value of the  derivative  liabilities  at  issuance  was based upon the
following management assumptions:

     Exercise price                                $4.00
     Expected dividends                                0%
     Expected volatility                             150%
     Expected term: warrants                      2 years
     Risk free interest rate                        0.74%

                                       10
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


MARK TO MARKET

At June 30,  2010,  the  Company  remeasured  the  derivative  liabilities,  and
recorded a fair value adjustment of $247. The following  management  assumptions
were considered:

     Exercise price                                 $4.00
     Expected dividends                                 0%
     Expected volatility                              150%
     Expected term: warrants                      2 years
     Risk free interest rate                         0.61%

NOTE 7 STOCKHOLDERS' EQUITY

I. FOUNDER SHARES, COMMON STOCK AND WARRANTS

YEAR ENDED DECEMBER 31, 2007

On June 28, 2007  (inception),  the Company  issued  6,350,000  shares of common
stock to founders and 400,000 shares of common stock to consultants  for a total
of $683 ($0.0001/share).

During 2007, the Company had the following private placement:

DECEMBER 28, 2007

*    3,819,227 units for $234,883 ($0.06/unit),
*    Each unit  consisted  of one  share of stock  (3,819,227)  and one  warrant
     (3,819,227 Series "A"),
*    Series "A" warrants have an exercise price of $0.20/share and an expiration
     date of two years,

YEAR ENDED DECEMBER 31, 2008

During 2008, the Company had the following private placements:

(A) JULY 15, 2008

*    304,000 units for $76,000 (0.25/unit),
*    Each  unit  consisted  of one  share of stock  (304,000)  and two  warrants
     (304,000 Series "A") and (304,000 Series "B"),
*    Series "A" warrants have an exercise price of $0.30/share and an expiration
     date of one year,
*    Series "B" warrants have an exercise price of $0.40/share and an expiration
     date of two years.

                                       11
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


(B) JULY 20, 2008

*    183,000 units for $55,000 ($0.30/unit),
*    Each  unit  consisted  of one  share of stock  (183,333)  and two  warrants
     (183,333 Series "A") and (183,333 Series "B"),
*    Series "A" warrants have an exercise price of $0.35/share and an expiration
     date of one year,
*    Series "B" warrants have an exercise price of $0.45/share and an expiration
     date of two years.

(C) DECEMBER 25, 2008

*    142,857 units for $50,000 ($0.35/unit),
*    Each  unit  consisted  of one  share of  stock  (142,857)  and one  warrant
     (142,857 Series "A"),
*    Series "A" warrants have an exercise price of $0.20/share and an expiration
     date of three years.

YEAR ENDED DECEMBER 31, 2009

During 2009, the Company had the following private placements:

(A) JULY 2, 2009

*    14,285 units for $5,000 ($0.35/unit),
*    Each unit consisted of one share of stock (14,285) and one warrant  (14,285
     Series "A"),
*    Series "A" warrants have an exercise price of $0.50/share and an expiration
     date of three years.

(B) JULY 22, 2009

*    57,143 units for $20,000 ($0.35/share)

(C) JULY 28, 2009

*    250,000 units for $75,000 ($0.30/unit),
*    Each  unit  consisted  of one  share of  stock  (250,000)  and one  warrant
     (250,000 Series "A"),
*    Series "A" warrants have an exercise price of $0.40/share and an expiration
     date of two years.

(D) NOVEMBER 23, 2009

*    111,111 units for $100,000 ($0.90/unit),
*    Each unit  consisted  of two  shares  of stock  (222,000)  and one  warrant
     (111,000 Series "A"),
*    Series "A" warrants have an exercise price of $0.60/share and an expiration
     date of two years.

                                       12
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


(E) DURING 2009, THE COMPANY HAD THE FOLLOWING WARRANT EXERCISES:

*    July 10, 2009 - 50,000 shares at $0.20/share for $10,000.
*    November 12, 2009 - 250,000 shares at $0.20/share for $50,000.
*    December 28, 2009 - 593,663 shares at $0.20/share for $118,732

SIX MONTHS ENDED JUNE 30, 2010

On April 30, 2010, the Company granted 200,000 warrants to acquire  intellectual
property from two  individuals.  These warrants have an exercise price of $1.00,
and expire in 2 years. The fair of these warrants is $52,960.

The Company  determined  the fair value of these share based payments based upon
the following assumptions:

     Expected term                            2 years
     Expected volatility                          150%
     Expected dividends                             0%
     Risk free interest rate                     0.97%
     Expected forfeitures                           0%

During 2010, The Company had the following private placement:

JUNE 23, 2010

*    25,000 units for $50,000 (2.00/unit),
*    Each unit consisted of one share of stock (25,000) and 1/2 warrant  (12,500
     Series "A"), and
*    Series "A" warrants have an exercise price of $4.00/share and an expiration
     date of two years.

See Note 6 as it pertains to  derivative  liabilities  being  recorded for these
warrants.

                                       13
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


The following is a summary of the Company's  warrants that are  outstanding  and
exercisable at June 30, 2010, December 31, 2009 and 2008:

<TABLE>
<CAPTION>
                                                                              Weighted
                                                                              Average
                                                                Weighted      Remaining
                                                                 Average     Contractual
                                                                Exercise      Life in      Intrinsic
                                                 Warrants        Price         Years         Value
                                                 --------        -----         -----         -----
<S>                                            <C>               <C>           <C>        <C>
Balance - December 31, 2008                      4,936,750        0.23          0.54
Granted                                            375,396        0.46
Forfeited/Cancelled                             (3,412,897)       0.22
Exercised                                         (893,663)       0.20
                                               -----------       -----
Balance - December 31, 2009 - outstanding        1,005,586        0.40          1.18         $   --
                                               ===========       =====         =====
Balance - December 31, 2009 - exercisable        1,005,586        0.40          1.18         $   --
                                               ===========       =====         =====
Granted                                            212,500        1.18
Exercised                                               --          --
Forfeited/Cancelled                                     --          --
                                               -----------       -----
Balance - June 30, 2010 - outstanding            1,218,086        0.54          0.88         $   --
                                               ===========       =====         =====
Balance - June 30, 2010  - exercisable           1,218,086        0.54          0.88         $   --
                                               ===========       =====         =====
</TABLE>

II. STOCK OPTIONS

(A) STOCK OPTION GRANT IN 2008

On December 20, 2008,  the Company  granted  100,000 stock options having a fair
value of $14,363 for services rendered.

(B) STOCK OPTION GRANT AND EXERCISE IN 2009

On September 25, 2009, the Company  granted  350,000 stock options having a fair
value of $36,519 for services rendered.

On September  25, 2009,  the Company  issued  192,857  shares of common stock in
connection  with a cashless  exercise  provision  related to all  450,000  stock
options previously granted.

(C) STOCK OPTION GRANT IN 2010

During the six months ended June 30, 2010, the Company  granted  3,886,938 stock
options,  having a grant date fair value of $1,604,607,  and recognized $242,359
of expense associated with these share based payments as follows:

                                       14
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


On January 1, 2010,  the Company  granted  800,000 stock options  having a grant
date fair value of $328,521,  which vest evenly over a thirty six month  period,
for services rendered.

On January 9, 2010, the Company  granted  1,886,938 stock options having a grant
date fair value of $783,702,  which vest evenly over a thirty six month  period,
for services rendered.

On February 1, 2010,  the Company  granted  200,000 stock options having a grant
date fair value of $82,069,  which vest over a two year  period,  quarterly,  at
50,000 shares  beginning  August 1, 2010 through  February 1, 2012, for services
rendered. These options are considered outstanding, but not exercisable.

On February 15, 2010, the Company granted 1,000,000 stock options having a grant
date fair value of $410,315,  which vest evenly over a thirty six month  period,
for services rendered.

The Company determined the fair value of its share based payments based upon the
following assumptions:

                                        2010          2009           2008
                                        ----          ----           ----
     Expected term                  5 years       2 years         2 years
     Expected volatility                150%          100%            100%
     Expected dividends                   0%            0%              0%
     Risk free interest rate      2.35-2.69%         0.30%           0.30%
     Expected forfeitures                 0%            0%              0%

                                       15
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


The following is a summary of the  Company's  options that are  outstanding  and
exercisable at June 30, 2010, December 31, 2009 and 2008:

<TABLE>
<CAPTION>
                                                                              Weighted
                                                                              Average
                                                                Weighted      Remaining
                                                                 Average     Contractual
                                                                Exercise      Life in      Intrinsic
                                                 Options         Price         Years         Value
                                                 -------         -----         -----         -----
<S>                                            <C>               <C>           <C>        <C>
Balance - December 31, 2008                       100,000         0.20
Granted                                           350,000         0.20
Exercised                                        (450,000)        0.20
Forfeited/Cancelled                                    --           --
                                               ----------        -----
Balance - December 31, 2009 - outstanding              --           --              --       $  --
                                               ==========        =====      ==========
Balance - December 31, 2009 - exercisable              --           --              --       $  --
                                               ==========        =====      ==========
Granted                                         3,886,938         0.40
Exercised                                              --           --
Forfeited/Cancelled                                    --           --
                                               ----------        -----
Balance - June 30, 2010 - outstanding           3,886,938         0.40      4.55 years       $  --
                                               ==========        =====      ==========
Balance - June 30, 2010 - exercisable             546,616         0.40      4.55 years       $  --
                                               ==========        =====      ==========
</TABLE>

NOTE 8 COMMITMENTS AND CONTINGENCIES

(A) LITIGATIONS, CLAIMS AND ASSESSMENTS

From time to time, the Company may become involved in various lawsuits and legal
proceedings, which arise in the ordinary course of business. However, litigation
is subject to inherent  uncertainties,  and an adverse  result in these or other
matters may arise from time to time that may harm its  business.  The Company is
currently  not aware of any such legal  proceedings  or claims that they believe
will have,  individually or in the aggregate,  a material  adverse affect on its
business, financial condition or operating results.

(B) EMPLOYMENT AGREEMENTS AND CONSULTING AGREEMENTS

In 2010, the Company entered into agreements with  individuals who will serve as
officers and directors. The terms of these agreements are as follows:

     1.   Chief Executive Officer (January 1, 2010)
          a.   Monthly fee of $6,000.
          b.   800,000 stock options having a grant date fair value of $328,521,
               which vest evenly over a thirty six month period.

                                       16
<PAGE>
                              Enox Biopharma, Inc.
                          Notes to Financial Statements
                                  June 30, 2010
                                   (Unaudited)


     2.   Chairman (January 9, 2010)
          a.   Entitled to receive  monthly cash payment based upon Company's on
               hand  cash  resources.  Currently,  the  Company  does  not  have
               sufficient resources to meet the agreed upon amounts.
          b.   1,886,938  stock  options  having  a grant  date  fair  value  of
               $783,702, which vest evenly over a thirty six month period.

     3.   Consultant (February 1, 2010)
          a.   Annual salary - $50,000
          b.   200,000 stock options  having a grant date fair value of $82,069,
               which vest over a two year period,  quarterly,  at 50,000  shares
               beginning August 1, 2010 through February 1, 2012. This agreement
               was terminated in July 2010.

     4.   Chief Financial Officer (February 15, 2010)
          a.   1,000,000  stock  options  having  a grant  date  fair  value  of
               $410,315, which vest evenly over a thirty six month period.

     5.   Investor Relations & Public Relations (March 15, 2010)
          a.   Monthly retainer of $8,000. Under the agreement until the company
               has  raised  capital in the  amount of at least  $3,000,000,  the
               company shall pay $2,500 per month,  whereas the remaining $5,500
               per month shall be deferred  until the  Investment  Threshold  is
               reached. This agreement was terminated in May 2010.

NOTE 9 SUBSEQUENT EVENTS

(A) WARRANT EXERCISE

On July  13,  2010,  the  Company  issued  183,333  shares  of  common  stock in
connection  with  warrants  that had been  exercised.  The  exercise of warrants
resulted in the Company receiving $82,500 ($0.45/share).

On July  15,  2010,  the  Company  issued  160,000  shares  of  common  stock in
connection  with  warrants  that had been  exercised.  The  exercise of warrants
resulted in the Company receiving $64,000 ($0.40/share).

(B) PRIVATE PLACEMENT - AUGUST 12, 2010

*    75,000 units for $150,000 (2.00/unit), of the total, 25,000 units each were
     sold to the Chairman of the Board and Chief Financial Officer,
*    Each unit consisted of one share of stock (75,000) and 1/2 warrant  (37,500
     Series "A"), and
*    Series  "A"  warrants  hpave  an  exercise  price  of  $4.00/share  and  an
     expiration date of two years.

See Note 6 as it pertains to  derivative  liabilities  being  recorded for these
similiar type warrants.

(C) OPTION GRANT

On August 1, 2010,  the Company  granted 10,000 stock options to a member of the
advisory board.  The options have an exercise price of $1.00/share.  The options
vest over a three year period as  follows:  1/3 each at the end of the month 12,
24, and 36.

                                       17
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
        OF OPERATIONS

FORWARD LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking  statements.
Forward-looking  statements  may include  our  statements  regarding  our goals,
beliefs,   strategies,   objectives,   plans,   including  product  and  service
developments,  future  financial  conditions,  results or projections or current
expectations.  In some cases,  you can identify  forward-looking  statements  by
terminology such as "may," "will,"  "should,"  "expect,"  "plan,"  "anticipate,"
"believe,"  "estimate,"  "predict,"  "potential" or "continue,"  the negative of
such terms, or other comparable  terminology.  Such  forward-looking  statements
appear in this Item 2 -  "Management's  Discussion  and  Analysis  of  Financial
Condition  and Results of  Operations,"  and include  statements  regarding  our
expectations  regarding our short - and long-term  capital  requirements and our
business plan and estimated expenses for the coming 12 months.  These statements
are subject to known and unknown  risks,  uncertainties,  assumptions  and other
factors  that may cause actual  results to be  materially  different  from those
contemplated by the forward-looking  statements.  The business and operations of
Enox  Biopharma,  Inc.  are subject to  substantial  risks,  which  increase the
uncertainty inherent in the forward-looking statements contained in this report.
We undertake  no  obligation  to release  publicly the result of any revision to
these  forward-looking  statements  that  may  be  made  to  reflect  events  or
circumstances   after  the  date  hereof  or  to  reflect  the   occurrence   of
unanticipated events. Further information on potential factors that could affect
our  business is described  under the heading  "Risks  Related To Our  Business,
Strategy,  And Industry" in Part I, Item 1, "Risk  Factors" in our  registration
statement on Form S-1 no 333-154763, which was declared effective on October 31,
2008.  Readers  are also urged to  carefully  review and  consider  the  various
disclosures we have made in this report.

OVERVIEW

Enox Biopharma, Inc. ("Enox", "us", "we" and "our") was incorporated on June 28,
2007 in the State of Nevada. We are a development stage  biotechnology  company,
and to  date  have  not  earned  any  revenue  and  currently  do not  have  any
significant  assets.  Our corporate offices are located at 303-1687 W. Broadway,
Vancouver BC, V6J 1X2,  Canada.  Our telephone  number is (604) 637-9744 and our
fax number is (888) 224-7259. We do not have any subsidiaries. We have a website
at www.enoxbiopharma.com, however, the information contained on our website does
not form part of this Quarterly Report.

We are focusing on the  development  and  commercialization  of advanced  Nitric
Oxide  technologies  for a variety of medical  uses.  Enox's  patented  platform
technology can be utilized across a wide spectrum of  applications  ranging from
the  treatment of upper  respiratory  tract  infections,  prevention of hospital
acquired infections (HAI),  innovative  solutions to assist in the prevention of
the common cold and to protect people from a diverse array of life  threatening,
drug resistant, infections.

During the fiscal  period  ending June 30, 2010 we expanded  our IP portfolio by
purchasing a worldwide patent  application from Nitricare.  The patent is issued
in China and South  Africa and is under  review in other  countries.  We further
strengthened   our  IP  by  submitting  two  new  patents  covering  methods  of
manufacturing  and of use and  entering  a national  phase for our first  patent
application.  We have  manufactured our first patented  charging devise which is
currently under field testings.  We have secured  diversification into a broader
nitric oxide based IP by signing a memorandum of agreement  with the  University
of British  Columbia.  Collectively  our efforts  will  provide us with a strong
foundation to further develop our global business opportunities.

RESULTS OF  OPERATIONS - THREE MONTHS ENDED JUNE 30, 2010  COMPARED TO THE THREE
MONTHS  ENDED JUNE 30, 2009 AND SIX MONTHS  ENDED JUNE 30, 2010  COMPARED TO THE
SIX MONTHS ENDED JUNE 30, 2009

During the three months ended June 30, 2010, we incurred  operating  expenses of
$408,420,  an increase of  $350,085 or  approximately  600% from the three month
ended June 30, 2009.  Operating  expenses increased during the three month ended
June  30,  2010  from the  comparative  period  due to  issuing  options  of the
consultant.

                                       18
<PAGE>
Other significant elements include:

     *    research  and  development  costs of  $98,396,  which  increased  from
          $41,462  during the same  period in the prior  year,  an  increase  of
          approximately  137%, due to prepaid  expenses and accrued  liabilities
          for research and development;
     *    general and administrative fees of $295,130, which is an increase from
          $16,873  during the same  period in the prior  year,  an  increase  of
          approximately 1,650%, due to increase in consulting, professional fess
          related to accounting and legal services, increase in travel and other
          related expenses;

During the six months ended June 30,  2010,  we incurred  operating  expenses of
$616,083,  an  increase  of  $516,132  from the six month  ended June 30,  2009.
Operating  expenses  increased during the six month ended June 30, 2010 from the
comparative  period due  primarily  to an  increase of legal,  professional  and
consulting  fees.  Consulting fees increased  $275,777  because of options being
vested for  consulting  services.  These  services  included  consulting for the
Company by the President and Director of the Company, a Director of the Company,
and the CFO of the company.  An increase of $78,812 in legal fees was the result
of  the  acquisition  of  international  patents  and  for  the  procurement  of
investments. Other consulting costs of $31,043 were incurred for a business plan
and patents.

Other significant issues were:

     *    Research and Development  expenses increased by $77,045,  travel costs
          increased $40,011.  These expenses were incurred during the process of
          seeking capital and for the procurement of patents.  Other  noteworthy
          increases  were in Investor  Relations,  having an increase of $20,598
          and a Derivative expense of $15,141.

NET LOSS

We  incurred  a net loss of  $616,083  for the six months  ended June 30,  2010,
compared to a net loss of $99,951 for the six months ended June 30, 2009.

LIQUIDITY AND CAPITAL RESOURCES

To date,  we have had  negative  cash  flows  from  operations  and we have been
dependent on sales of our equity  securities to meet our cash  requirements.  We
expect this situation to continue for the foreseeable future. We anticipate that
we will have  negative  cash  flows from  operations  in the next  twelve  month
period.

As of June 30, 2010, we had cash of $148,878 representing a net decrease in cash
of $85,196 since December 31, 2009.

There was $50,000 cash generated by financing  activities  during the six months
ended  June 30,  2010.  In May,  the  Company  accepted  a loan in the amount of
$100,000 from G.N.E.  Biotechnologies  which is due in full on or before May 15,
2011. Interest payments of 12%, or $1,000 are paid each month.

Because we have not  generated  any revenue from our  business,  we will need to
raise additional funds for the future development of our business and to respond
to unanticipated  requirements or expenses. We believe our current cash balances
will be extinguished by the fourth quarter of 2010,  provided we do not have any
unanticipated  expenses. We do not currently have any arrangements for financing
and we can  provide  no  assurance  to  investors  we will be able to find  such
financing. There can be no assurance that additional financing will be available
to us,  or on terms  that are  acceptable.  Consequently,  we may not be able to
proceed  with our  intended  business  plans or  complete  the  development  and
commercialization of our product.

If we fail to generate sufficient net revenues, we will need to raise additional
capital  to  continue  our  operations  thereafter.  We  cannot  guarantee  that
additional  funding  will be  available  on  favorable  terms,  if at  all.  Any
shortfall will affect our ability to expand or even continue our operations.  We
cannot  guarantee that additional  funding will be available on favorable terms,
if at all.

                                       19
<PAGE>
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4/4T. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

As required by Rule 13a-15/15d-15 under the Securities and Exchange Act of 1934,
as amended (the  "Exchange  Act"),  as of June 30, 2010,  we have carried out an
evaluation  of the  effectiveness  of the design and  operation of our Company's
disclosure  controls and  procedures.  This evaluation was carried out under the
supervision  and  with  the  participation  of  our  Company's  management,  our
President  (Principal  Executive  Officer) and Treasurer  (Principal  Accounting
Officer).  Based  upon  the  results  of that  evaluation,  our  management  has
concluded  that,  as of June 30, 2010,  our  Company's  disclosure  controls and
procedures  were  effective  and  provide  reasonable  assurance  that  material
information  related to our Company required to be disclosed in the reports that
we file or submit under the Exchange Act is recorded, processed,  summarized and
reported  within the time periods  specified  in the SEC's rules and forms,  and
that such  information is accumulated  and  communicated  to management to allow
timely decisions on required disclosure.

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for  establishing  and maintaining  adequate  internal
control over  financial  reporting as defined in Rules  13a-15(f)  and 15d-15(f)
under the  Exchange  Act.  Our  internal  control  system is designed to provide
reasonable  assurance to our  management  and board of directors  regarding  the
reliability of financial  reporting and the preparation of financial  statements
for external reporting purposes in accordance with generally accepted accounting
principles.  Our  internal  control  over  financial  reporting  includes  those
policies and procedures that:

* Pertain to the maintenance of records that, in reasonable  detail,  accurately
and  fairly  reflect  the  transactions  and  dispositions  of the assets of the
Company;  * Provide  reasonable  assurance  that  transactions  are  recorded as
necessary to permit  preparation  of financial  statements  in  accordance  with
generally accepted  accounting  principles in the United States of America,  and
that receipts and  expenditures of the Company are being made only in accordance
with  authorizations  of management and directors of the Company;  and * Provide
reasonable  assurance  regarding  prevention or timely detection of unauthorized
acquisition,  use or  disposition  of the  Company's  assets  that  could have a
material effect on the financial statements.

Management  assessed the  effectiveness  of our internal  control over financial
reporting as of June 30, 2010. In making this  assessment,  we used the criteria
set  forth  by  the  Committee  of  Sponsoring  Organizations  of  the  Treadway
Commission (COSO) in Internal Control -- Integrated Framework.

Because of the material  weaknesses  described below, our management,  under the
supervision of and with the  participation  of our Chief  Executive  Officer and
Chief  Financial  Officer,  concluded  that,  as of June 30, 2010,  our internal
control over  financial  reporting  was not  effective  based on the criteria in
Internal Control -- Integrated Framework issued by the COSO.

A material weakness is a deficiency, or combination of deficiencies, in internal
control over  financial  reporting  such that there is a reasonable  possibility
that a material  misstatement  of our annual or interim  consolidated  financial
statements will not be prevented or detected on a timely basis.

In our  assessment  of the  effectiveness  of internal  control  over  financial
reporting  as of June 30,  2010,  we  identified  that our  material  weaknesses
derived  from the small  size of our  Company.  That small size makes the proper
identification  and  authorization  of  transactions   difficult,   as  we  have
essentially  only two  individuals  overseeing  this process,  which and creates
difficulties  with  separation  of duties  for  handling,  approving  and coding
invoices,  entering transactions into the accounts,  writing checks and requests
for wire transfers. Additionally, the Company's officers are also its sole board
members. This does not provide an adequate level of layers of internal controls,

                                       20
<PAGE>
which  in turn  make it  difficult  to  accumulate  information  required  to be
disclosed  by our  Company in the  reports  that it files or  submits  under the
Exchange Act.

This  annual  report  does not include an  attestation  report of the  Company's
independent  registered public  accounting firm regarding  internal control over
financial  reporting.  Management's report was not subject to attestation by the
Company's  independent  registered  public accounting firm pursuant to temporary
rules of the SEC that permit the Company to provide only management's  report in
this annual report.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There  were  no  changes  in  our  internal  control  over  financial  reporting
identified in connection with the evaluation  described above during the quarter
ended June 30,  2010 that has  materially  affected or is  reasonably  likely to
materially affect our internal controls over financial reporting.

                           PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

(a) Pursuant to Rule 601 of Regulation  SK, the following  exhibits are included
herein or incorporated by reference.

Exhibit
Number                               Description
------                               -----------

31.1     Certification of Acting CEO Pursuant to 18 U.S.C. ss. 1350, Section 302

31.2     Certification of CFO Pursuant to 18 U.S.C. ss. 1350, Section 302

32.1     Certification Pursuant to 18 U.S.C. ss.1350, Section 906

32.2     Certification Pursuant to 18 U.S.C. ss. 1350, Section 906

                                       21
<PAGE>
                                   SIGNATURES

Pursuant to the  requirements of Section 13 or 15(d) of the Securities  Exchange
Act of 1934,  the  registrant  has duly  caused  this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                Enox Biopharma, Inc.


                                By: /s/ Prof. Yossef Av-Gay
                                    --------------------------------------------
                                    Prof. Yossef Av-Gay, Acting Chief Executive
                                    Officer (Principal Executive Officer)
                                    Dated: August 16, 2010


                                By: /s/ Itamar David
                                    --------------------------------------------
                                    Mr. Itamar David, Chief Financial Officer
                                    (Principal Financial and Accounting Officer)
                                    Dated: August 16, 2010

Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.


                                By: /s/ Prof. Yossef Av-Gay
                                    --------------------------------------------
                                    Prof. Yossef Av-Gay, Acting Chief Executive
                                    Officer (Principal Executive Officer)
                                    Dated: August 16, 2010


                                By: /s/ Itamar David
                                    --------------------------------------------
                                    Mr. Itamar David, Chief Financial Officer
                                    (Principal Financial and Accounting Officer)
                                    Dated: August 16, 2010


                                By: /s/ Amir Avniel
                                    --------------------------------------------
                                    Mr. Amir Avniel, Chairman of the Board of
                                    Directors
                                    Dated: August 16, 2010

                                       22